Antibody Mediated Rejection clinical trials at UCSF
1 research study open to eligible people
Antibody mediated rejection is when a transplanted kidney is attacked by the body's own immune system. UCSF is recruiting for a clinical trial testing clazakizumab, a treatment designed to stop this attack. The goal is to see if clazakizumab is effective and safe for kidney transplant recipients with chronic active antibody mediated rejection.
Showing trials for
Clazakizumab for the Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant Recipients
open to eligible people ages 18-75
This trial investigates the efficacy and safety of clazakizumab [an anti-interleukin (IL)-6 monoclonal antibody (mAb)] for the treatment of CABMR in recipients of a kidney transplant.
San Francisco, California and other locations
Last updated: